| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 1997 American Heart Association, Inc.
Articles |
Effect of Serum Lipids, Lipoproteins, and Apolipoproteins on Vascular and Nonvascular Mortality in the Elderly
From the Department of Geriatrics, University of Turku, Turku, Finland (I.R., L.S.); the Research and Development Centre of the Social Insurance Institution, Turku, Finland (J.M., P.P., T.T.); and the Department of Biochemistry, National Public Health Institute, Helsinki, Finland (C.E.).
Correspondence to I. Räihä, Department of Geriatrics, University of Turku, Kunnallissairaalantie 20, FIN-20700 Turku, Finland.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract The purpose of this study was to determine the effect of serum lipids, lipoprotein fractions, and apolipoprotein (apo) A-1, B, and E on mortality from vascular and nonvascular causes in an unselected elderly population. The random sample of 347 community-living individuals aged 65 years or older was obtained in 1982. Serum total cholesterol, LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), triglyceride, and apo A-1, B, and E were determined at baseline. After the 11-year follow-up, 199 of the participants had died, and 148 were still alive. Mortality data from vascular and nonvascular causes by the end of 1993 were obtained from official registers. In the univariate analysis, a low total cholesterol level was associated with death due to both vascular and nonvascular causes (P value for trend, .021 and .0027, respectively). After the adjustment for other risk factors, the inverse association between total cholesterol and vascular mortality disappeared, but low total cholesterol was still a significant predictor of death due to nonvascular causes. Adjusted relative risks (RRs) of death due to nonvascular causes for those with elevated total cholesterol (5.1 to 6.5, 6.6 to 8.0, and >8.0 mmol/L) compared with the reference group (
5.0 mmol/L) were 0.5 (95%
confidence interval [CI], 0.2 to 1.2), 0.6 (0.2 to 1.0), and 0.2 (0
to 0.8), respectively. Neither concentrations of HDL-C, LDL-C,
triglyceride, nor apo B were associated with vascular or
nonvascular mortality. On the other hand, low concentration of apo A-1
predicted vascular death. The RR for the lowest tertile was 1.6 (1.1 to
2.5) compared with the highest tertile. Furthermore, the occurrence of
the apo E e4 allele was associated with increased risk of vascular
mortality (RR, 1.5; 95% CI, 1.0 to 2.2), but the risk was not related
to the levels of lipids, lipoproteins, or other apolipoproteins at
baseline. Nonvascular mortality also tended to be predicted by the
presence of the e4 allele (RR, 1.5; 95% CI, 0.9 to 2.5). In an
unselected elderly population, the allelic variation of apo E, ie, the
presence of the e4 allele, and a low concentration of apo A-1 were
more accurate indicators of vascular mortality than total
cholesterol or lipoprotein fractions. The risk associated
with the apo E polymorphism is unrelated to
dyslipidemia.
Key Words: apolipoprotein A-1 • apolipoprotein E • cholesterol • coronary heart disease • elderly • mortality • prognosis
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The relationship between elevated serum total cholesterol and LDL-C concentrations, low HDL-C concentrations, and coronary heart disease in middle age1 2 3 4 and early old age has been established.5 In old age, however, the association between total cholesterol and coronary heart disease tends to disappear or even becomes inverse; therefore, the prognostic significance of cholesterol and lipoprotein fractions has remained controversial in this age group.1 6 7 8 9 10 11 Several studies have suggested an association between low serum cholesterol and such diseases as cancer and chronic respiratory diseases12 13 14 15 as well as certain lifestyle risk factors, such as heavy alcohol use and smoking.16 17 18 It has been proposed that the inverse association between cholesterol level and mortality from noncardiac causes is a result of these confounding factors.15 16 18 Because of this, it has been suggested that lipoprotein fractions and apolipoproteins can predict cardiovascular risk in the elderly more reliably than total cholesterol concentration.19 20 21
Variation in apo E phenotype has been found to affect lipoprotein levels. Three common apo E alleles, e2, e3, and e4, have been identified. The e4 allele increases intestinal cholesterol absorption, affects LDL synthesis in the liver,22 and is associated with elevated levels of total cholesterol and LDL-C23 24 25 26 and a higher prevalence of atherosclerosis.27 The association between apo E polymorphism and coronary heart disease has been found in several cross-sectional populations.28 29 30 31 Recently, results from the first longitudinal study (with 5-year follow-up) indicated that the e4 allele predicted death from coronary heart disease in elderly men.32 Nevertheless, information about the prognostic importance of the e4 allele in unselected populations is scarce.
The aim of this longitudinal study was to examine the prognostic impact of serum total cholesterol, LDL-C, HDL-C, triglyceride, and apo A-1, B, and E on death due to vascular and nonvascular causes in an unselected elderly population, taking into account the contribution of other risk factors at screening.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Subjects
In 1982 a large survey of the health status of the elderly was carried out in the city of Turku, Finland. A random sample of 480 community-living individuals aged 65 years and older, stratified into four age groups (65 through 69, 70 through 74, 75 through 79, and 80 years and older), with men and women grouped separately, was obtained from the register of the Social Insurance Institution. No exclusion criteria other than living in an institution were used. The participation rate was 72%; thus, the population consisted of 347 subjects (Table 1
). Of these, 184 were men, and 163 were
women. The reasons for nonparticipation were as follows: illness in 48
subjects, attitude in 50, social problems in 3, and unknown in 32. A
full history was obtained and a complete clinical evaluation was
performed in all 347 participants.
|
Clinical Examination
The clinical history was obtained by personal interview. A
comprehensive clinical evaluation, including physical examination,
standard electrocardiography, chest x-ray,
blood pressure measurement, routine biochemical analysis, and
weight and height measurements (expressed as body mass index), was
carried out. Major vascular diagnoses were established on the basis of
the history and clinical evaluation. Ischemic heart disease was
diagnosed when there was a standard history of angina
pectoris.33 Myocardial infarction was recorded as
present on the basis of Q wave abnormalities on the
electrocardiogram, which were coded according to the
Minnesota code.34 Congestive heart failure was considered
to be present when typical findings were found on chest x-ray.
Cerebral artery disease was diagnosed if there was evidence of focal
neurological symptoms or signs. Moreover, additional information was
obtained from the national health insurance documents of the subjects.
These documents include information on entitlement to preferential
refund of medication expenses because of common chronic diseases. To
get this entitlement, a complete clinical evaluation is needed. If a
subject was eligible for refund of medication expenses because of
diabetes, hypertension, ischemic heart disease, congestive
heart failure, or chronic bronchitis with pulmonary emphysema,
that diagnosis was recorded as present.
Chemical Analyses
Serum total cholesterol, HDL-C, LDL-C,
triglyceride, and apo A-1, B, and E were measured using
overnight fasting samples drawn in 1982. All other lipid
parameters except apo E phenotyping were analyzed
in 1982 on a daily basis after the samples were taken or after 2 to 3
months of storage at -70°C. Serum total cholesterol was
determined by the enzymatic cholesterol
esterase–cholesterol oxidase method (Boehringer
Mannheim, Mannheim, Germany). HDL-C was measured after
dextran–sulphate precipitation of serum35 with the same
enzymatic method. Serum triglycerides were determined with
the enzymatic ultraviolet method (Boehringer Mannheim). The
concentration of serum apo A-1 (reference values, 0.86 to 1.46 g/L) was
determined by radioimmunoassay as described earlier.36 Apo
B (reference values 0.92 to 1.33 g/L)36 was
analyzed by immunoturbidometry according to Riepponen et
al37 (Orion Diagnostica, Espoo, Finland).
Serum LDL-C was calculated using the Friedewald formula.38
Apo E phenotyping was carried out from serum samples stored frozen
(-40 C) by isoelectric focusing and immunoblotting
after removal of serum lipids.39
Follow-up
In 1994 the 11-year mortality rate of subjects and causes of
deaths were obtained from the mortality statistics. One hundred
ninety-nine (57%) of the participants had died, and 148 were still
alive (Table 1
). In 127 subjects, death was caused by vascular disease.
In 54 (43%), diagnosis of vascular death was confirmed at autopsy. The
vascular deaths were predominantly caused by coronary events,
cerebral infarcts, or sudden cardiac death. In 72 subjects, death was
due to nonvascular causes, and autopsy was carried out in 31 of these
subjects (43%). The causes of death are given in Table 2. To determine the effect of blood lipids on the
11-year mortality rate, lipid values of subjects who were alive on
January 1, 1994, and those of subjects who had died as a result of
either vascular or nonvascular causes by that same date were
compared.
|
Statistical Analysis
The SAS (Statistical Analysis System, version 6) program
package was used for the analyses. The Student's t
test was used to compare mean values of normally distributed numerical
variables. Product-limit (Kaplan-Meier) survival curves were
calculated for various total cholesterol levels. The curves
of these cholesterol data were compared using the log rank
test. RRs (hazard ratios with 95% CIs) for the 11-year vascular and
nonvascular mortality rates were calculated using the Cox proportional
hazards model according to blood lipids, adjusting for other risk
factors. Adjustment was made for age, sex, smoking, alcohol
use, body mass index, coronary heart disease, hypertension, and
diabetes. Age and body mass index were fitted continuously in the
model, and sex, smoking (never, former, and current smoker), alcohol
use (never, 1 to 2 drinks per week, and more than 2 drinks per week),
and the presence of coronary heart disease (none, probable, or
definite), diabetes (none or definite), and hypertension (none or
definite) were fitted as categorical variables.
Cholesterol was fitted at four levels (5.0, 5.1 to 6.5,
6.6 to 8.0, and >8.0 mmol/L); HDL-C, at three levels (<1.2, 1.2
to 1.7, and >1.7 mmol/L); LDL-C, at three levels (<3.5, 3.5 to
5.0, and >5.0 mmol/L); and triglyceride and apo E, at
two levels (<2.0 and >2.0 mmol/L and e4 allele
absent or present, respectively). Apo A-1 and B (g/L) were divided
into tertiles and fitted at three levels (lowest, middle, and highest
tertiles). To assess the adequacy of the Cox model, the interactions of
age and other risk factors were tested with logistic regression. The
Cox model proved to be adequate in all but the analysis of
effect of HDL-C and apo A1 on nonvascular mortality, in which slight
interactions between HDL-C and age (P=.05) and between apo
A1 and age (P=.04) were observed. To examine the possible
effects of preexisting diseases on mortality, deaths that occurred
during the first 4 years of follow-up (1982 through 1985) were excluded
from the further analysis of total cholesterol, and
adjusted RRs were calculated using data from 1986 through 1993.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The baseline characteristics of subjects grouped by mortality are given in Table 3
. The mean concentrations of serum
lipids, lipoproteins, and apolipoproteins in different age groups
according to outcome are presented in Fig 1.
Kaplan-Meier survival curves for vascular and nonvascular mortality,
stratified by total serum cholesterol level, are shown in
Figs 2 and 3. Low total
cholesterol level was associated with death due to both
vascular (P=.021) and nonvascular causes
(P=.0027). Adjusted RRs according to lipids, lipoproteins,
and apo A-1, B, and E are given in Table 4. After
adjustment forother risk factors, the inverse association between total
cholesterol and vascular mortality disappeared, but low
total cholesterol was still a significant predictor of
nonvascular death. RRs of death due to nonvascular causes for those
with elevated total cholesterol (5.1 to 6.5, 6.6 to 8.0,
and >8.0 mmol/L) compared with the reference group (5.0
mmol/L) were 0.5 (95% CI, 0.2 to 1.2), 0.6 (0.2 to 1.0), and 0.2 (0 to
0.8), respectively. Concentrations of HDL-C, LDL-C,
triglyceride, or apo B were not associated with vascular or
nonvascular mortality. On the other hand, a low concentration of apo
A-1 predicted vascular death. The RR for the lowest tertile was 1.6
(1.1 to 2.5) compared with the highest tertile. When the mortality data
from the first 4 years (1982 to 1985) was excluded from the
further analysis of total cholesterol, the
distribution of deaths did not change, indicating that the mortality
rate obtained for the first 4 years did not differ from that obtained
later.
|
|
|
|
|
The occurrence of the apo E e4 allele (Table 4) was associated with
vascular mortality (RR, 1.5; 95% CI, 1.0 to 2.2), and a tendency of
the e4 allele to predict nonvascular mortality was observed (RR,
1.5; 95% CI, 0.9 to 2.5). The adjusted RRs of vascular and nonvascular
death according to the presence of the apo E e4 allele were
analyzed separately for each age group (Table 5). A significant increase in risk was observed in two
age groups, 70 to 74 and 75 to 79 years. The distribution of apo E
phenotypes and gene frequencies grouped by mortality are shown
in Table 6. The unadjusted figures of phenotypes
or gene frequencies of alleles e2, e3, and e4 did not differ
between subjects who were alive or those who had died. The mean
concentrations of lipids, lipoproteins, and apo A-1 and B in subjects
with and without the apo E e4 allele are shown in Table 7. The concentrations of total cholesterol,
LDL-C, and apo B were significantly higher in the group with the e4
allele. The concentrations of HDL-C, apo A-1, or
triglyceride did not differ according to the presence of an
apo E allele.
|
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
An elevated total serum cholesterol level did not predict vascular mortality but was a strong predictor of survival from death due to nonvascular causes. There are several possible explanations for the absence of a positive association between total cholesterol and vascular mortality. First, the total cholesterol level in the elderly may not represent their lifetime exposure, because many lifestyle factors and diseases may modulate it with advancing age.11 Thus, total cholesterol values measured in old age may differ considerably from levels determined by genetic and dietary factors in young and middle age. Second, it is possible that the elderly study population was already selected at baseline according to cholesterol level and that those who remained in the cohort may have been relatively resistant to the effects of lipids. It is known that the reference values of serum total cholesterol do not increase with advancing age in men but do in women.40 Third, a selection bias may have been caused by the nonparticipation of individuals with a low total cholesterol level and good health. In the present study, the inverse association between total cholesterol and nonvascular mortality was probably caused by the confounding of secondary reduction of total cholesterol concentration due to age-related lifestyle factors or preexisting diseases. This inverse association was further analyzed by excluding the first 4 years of mortality data after the screening and analyzing the years 1986 through 1993 separately. Nevertheless, the inverse association was still detected, suggesting that chronic diseases with a relatively long-term prognosis rather than disseminated cancer or other diseases with a poor short-term prognosis were responsible for the deaths. The negative association between total cholesterol and cancer mortality may persist for 18 years after screening, even when deaths occurring during the early follow-up period are excluded.41 42 Our findings confirm that total cholesterol concentration is sensitive to many factors, making it an unreliable marker for estimating cardiovascular risk in the elderly. However, the conclusion that a high total cholesterol concentration protects against vascular or nonvascular mortality cannot be drawn.15
It has been suggested that LDL-C indicates cardiovascular risk in elderly individuals better than total cholesterol.43 A recent study provides evidence that low HDL-C is associated with increased coronary heart disease mortality in older age groups.21 Furthermore, low values of LDL-C and high values of HDL-C have been found in octo-and nonagenarian survivors.44 In the present study, however, no association between LDL-C or HDL-C and vascular mortality was found.
Little data exist on the importance of apo A-1 as a vascular risk factor among the elderly. Longitudinal studies do not exist. Patients with myocardial infarction had lower values of apo A-1 compared with controls in the study of Avogaro et al.20 On the other hand, apo A-1 was not associated with coronary heart disease in a cross-sectional study of elderly men.45 In our popuation, the low concentration of apo A-1 was the strongest predictor of vascular death, whereas HDL-C showed no prognostic significance. In survivors as well as nonsurvivors, the concentration of apo A-1 was lower than previously reported in Finland in the middle-aged population24 and among elderly men.45
In cross-sectional samples, the apo E e4 allele has been found to increase the risk of coronary heart disease.30 31 46 Also, the high prevalences of the e4 allele24 and coronary heart disease in Finns and the low prevalences of the e4 allele and coronary heart disease in Chinese47 and Japanese48 populations support the concept of the e4 allele as an important indicator of atherosclerotic disease. In the study of Stengård et al, the unadjusted analysis of elderly men showed that the e4 allele predicted excess mortality due to coronary heart disease. In our study, the apo E allele frequencies were comparable with frequencies in the Finnish population, including youths.24 32 39 Adjusted vascular mortality was 50% higher in subjects with the e4 allele than in those without the e4 allele. The association was strongest in the 70- to 79-years age group but nonsignificant in subjects aged 80 or more years. However, there were only 8 survivors in the highest age group. In subjects having the e4 allele, total cholesterol, LDL-C, and apo B concentrations have been found to be higher than in subjects with other alleles.24 26 Also, in the present study, total cholesterol, LDL-C, and apo B concentrations were significantly higher in subjects with the e4 allele than in those without the e4 allele. The lack of association between total cholesterol and LDL-C and vascular mortality, however, suggests that the risk was not related to dyslipidemia. It is possible that the cardiovascular risk associated with the e4 allele is mediated not only by dyslipidemia but also by other mechanisms. Apo E is involved in the immune system and tissue regeneration, which makes possible a direct contribution to the atherogenic process at the cellular level in the arterial wall.49 50 Moreover, the association between the e4 allele and Alzheimer's disease suggests that unknown mechanisms, unrelated to serum lipids but involving the risk of atherosclerosis, may exist.
When cardiovascular risk due to dyslipidemia is evaluated, the selection of subjects is essential because lipids, especially total cholesterol, also reflect other factors as inheritance and diet. In the present study, random selection was used, and other risk factors were controlled by means of multivariate analysis. The response rate was 72%, which is not as high as one might wish. It is, however, comparable with that of studies including ambulatory electrocardiographic monitoring and comprehensive evaluation of health status. In this kind of study, cooperation and a positive attitude are needed. The unselected elderly study population also included a number of frail individuals. The low response rate may have caused some selection bias since the frail and sick individuals could have been those who did not respond and whose blood lipids underwent secondary changes. In the present study, however, the number of subjects who did not attend because of illness was considerably small, around 10% of the sample. In addition, the inverse association between total cholesterol and mortality due to nonvascular causes suggests that this kind of selection was unlikely. Rather, individuals with low total cholesterol level and good health or individuals with elevated total cholesterol and poor short-term prognosis did not attend. The prevalences of preexisting diseases were comparable with those in the large Finnish population study with age groups of 65 to 99 years carried out in 1978 to 1981.51 This also suggests that the significant selection bias did not take place in our study. Although the sample size was smaller than in some previous cohort studies, a large number of deaths occurred during the long follow-up period, yielding sufficient statistical power. The methods for the determination of apo A-1 and B were new in 1982, and one can propose that the standardization of the methods was not accurate at that time. However, the levels of apolipoproteins presented in our study are comparable with those observed in other Finnish studies, suggesting that our results are valid.36 52
In conclusion, in this cohort of elderly people, the predictive value of blood lipids differed from that of middle-aged people. The prognostic impact of elevated total cholesterol as a cardiovascular risk factor disappeared with aging but predicted survival in subjects with nonvascular diseases. HDL-C and LDL-C had no pre-dictive value. The presence of the apo E e4 allele and a low concentration of apo A-1 proved to be the only predictors of vascular mortality. The risk associated with the apo E e4 allele was not related to dyslipidemia. Thus, the apo E e4 allele and a low concentration of apo A-1 are obviously more reliable indicators of cardiovascular risk in elderly people than lipoprotein fractions or total cholesterol, because the latter are affected by age-related confounding factors.
|
Selected Abbreviations and Acronyms |
|---|
|
Received February 8, 1996; accepted August 10, 1996.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA. 1987;257:2176-2182.
2.
Gordon DJ, Probstfield JL, Garrison RI, Neaton JD,
Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA.
High-density lipoprotein cholesterol and
cardiovascular disease: four prospective American
studies. Circulation. 1989;79:8-15.
3.
Jacobs DR, Mebane IL, Bangiwala SI, Criqui MH, Tyroler
HA. High density lipoprotein cholesterol as a
predictor of cardiovascular disease mortality in men
and women: the follow-up study of the Lipid Research Clinic Prevalence
Study. Am J Epidemiol. 1990;131:32-47.
4.
Verschuren WMM, Kromhout D. Total
cholesterol concentration and mortality at relatively young
age: do men and women differ? BMJ. 1995;311:779-783.
5. Barrett-Connor E, Suarez L, Khaw KT, Criqui MH, Wingard DL. Ischaemic heart disease risk factors after age 50. J Chronic Dis. 1984;37:903-908.[Medline] [Order article via Infotrieve]
6. Harris T, Cook EF, Kannel WB, Goldman L. Proportional hazard analysis of risk factors for coronary heart disease in individuals aged 65 or older. J Am Geriatr Soc. 1988;36:1023-1028.[Medline] [Order article via Infotrieve]
7. Staessen J, Amery A, Birkenhäger W, Bulpitt C, Clement D, de Leeuw P, Deruyttere M, De Schaepdryver A, Dollery C, Fagard R, Fletcher A, Forette F, Forte J, Henry J-F, Koistinen A, Leonetti G. Is a high serum cholesterol level associated with longer survival in elderly hypertensives? J Hypertens. 1990;8:755-761.[Medline] [Order article via Infotrieve]
8.
Zimetbaum P, Frishman WH, Ooi WL, Derman MP, Aronson
M, Gidez LI, Eder HA. Plasma lipids and lipoproteins and the
incidence of cardiovascular disease in the very
elderly: the Bronx Aging Study. Arterioscler Thromb. 1992;12:416-450.
9.
Kronmal RA, Cain KC, Ye Z, Omenn GS. Total
serum cholesterol levels and mortality risk as a function
of age: a report based on the Framingham data. Arch
Intern Med. 1993;153:1065-1073.
10.
Krumholz HM, Seeman TE, Merrill SS, de Leon MCF,
Vaccarino V, Silverman DI, Tsukahara R, Ostfeld AM, Berkman LF.
Lack of association between cholesterol and
coronary heart disease mortality and morbidity and all-cause
mortality in persons older than 70 years. JAMA. 1994;272:1335-1340.
11. Lindberg O, Iivanainen M, Strandberg TE, Valvanne J, Tilvis RS. Low cholesterol, morbidity and mortality in the elderly: experience from the Helsinki Ageing Study. Cardiovasc Risk Factors. 1995;5:1-5.
12.
Sherwin RW, Wentworth DN, Cutler JA, Hulley LH, Stamler
J. Serum cholesterol levels and cancer mortality in
361 662 men screened for the Multiple Risk Factor Intervention
Trial. JAMA. 1987;257:943-948.
13. Schatzkin A, Hoover RN, Taylor PR, Ziegler RG, Carter CL, Larson DB. Serum cholesterol and cancer in the NHANES epidemiologic follow-up study. Lancet. 1987;ii:298-301.
14.
Davey-Smith G, Shipley MJ, Marmot MG, Rose G.
Plasma cholesterol and mortality: the Whitehall
Study. JAMA. 1992;267:70-76.
15.
Wannamethee G, Shaper AG, Whincup PH, Walker M.
Low serum cholesterol concentrations and mortality in
middle-aged British men. BMJ. 1995;311:409-413.
16.
Jacobs D, Blackburn H, Higgins M, Reed D, Iso H,
McMillan G, Neaton J, Nelson J, Potter J, Rifkind B, Rossouw J,
Shekelle R, Yusuf S. Report of the Conference on Low Blood
Cholesterol: mortality associations.
Circulation. 1993;86:1046-1060.
17.
Wannamethee G, Shaper AG. Blood lipids: the
relationship with alcohol intake, smoking and body weight.
J Epidemiol Community Health. 1992;46:197-202.
18.
Law MR, Thompson SG, Wald NJ. Assessing possible
hazards of reducing serum cholesterol.
BMJ. 1994;308:373-379.
19. Genest JJ, McNamara JR, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol. 1991;67:1185-1189.[Medline] [Order article via Infotrieve]
20. Avogaro P, Bittolo Bon G, Gazzolato G, Quinci GB. Are apolipoproteins better discriminators than lipids for atherosclerosis? Lancet. 1979;901-903.
21.
Corti M-C, Guralnik JM, Salive ME, Harrsi T, Field TS,
Wallace RB. HDL cholesterol predicts
coronary heart disease mortality in older persons.
JAMA. 1995;274:539-544.
22. Kesäniemi YA, Ehnholm C, Miettinen T. Intestinal cholesterol absorption efficiency in man is related to apolipoprotein E phenotype. J Clin Invest. 1987;80:578-581.
23. Utermann G, Kindermann I, Kaffarnik H, Steinmetz A. Apolipoprotein E phenotypes and hyperlipidemia. Hum Genet. 1984;65:232-236.[Medline] [Order article via Infotrieve]
24. Ehnholm C, Lukka M, Kuusi T, Nikkilä E, Uterman G. Apolipoprotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentrations. J Lipid Res. 1986;27:227-235.[Abstract]
25. Sing CF, Davignon J. Role of apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet. 1985;37:268-285.[Medline] [Order article via Infotrieve]
26.
Tikkanen MJ, Huttunen JK, Ehnholm C, Pietinen P.
Apoliprotein E homozygosity predisposes to serum
cholesterol elevation during high fat diet.
Arteriosclerosis. 1990;10:285-288.
27.
Davignon J, Gregg RE, Sing CF. Apolipoprotein E
polymorphism and atherosclerosis.
Arteriosclerosis. 1988;8:1-21.
28.
Menzel H-J, Kladetzky R-G, Assmann G.
Apolipoprotein E polymorphism and coronary artery
disease. Arteriosclerosis. 1983;3:310-315.
29.
Kuusi T, Nieminen MS, Ehnholm C, Yki-Jarvinen H, Valle
M, Nikkila EA, Taskinen M-R. Apolipoprotein E polymorphism
and coronary artery disease: increased prevalence of
apolipoprotein E-4 in angiographically verified coronary
patients. Arteriosclerosis. 1989;9:237-241.
30. Laakso M, Kesäniemi A, Kervinen K, Jauhiainen M, Pyörälä K. Relation of coronary heart disease and apolipoprotein E phenotype in patients with non-insulin dependent diabetes. BMJ. 1991;303:1159-1162.
31. van Bockxmeer FM, Mamotte CDS. Apolipoprotein e4 homozygosity in young men with coronary heart disease. Lancet. 1992;340:879-880.[Medline] [Order article via Infotrieve]
32.
Stengård JH, Zerba KE, Pekkanen J, Ehnholm C, Nissinen
A, Sing CF. Apolipoprotein E polymorphism predicts death
from coronary heart disease in a longitudinal study of elderly
Finnish men. Circulation. 1995;91:265-269.
33. Rose GA, Blackburn H. Cardiovascular Survey Methods. Geneva, Switzerland: World Health Organization; 1968:56.
34. Criteria Committee, New York Heart Association. Nomenclature and Criteria for Diagnosis and Disease of the Heart and Great Vessels. 8th ed. Boston, Mass: Little, Brown, & Co; 1979:188-250.
35. Kostner GM. Enzymatic determination of cholesterol in high-density lipoprotein fractions prepared by polyanion precipitation. Clin Chem. 1976;22:695.
36. Lehtonen A, Marniemi J, Inberg M, Maatela J, Alanen E, Niittymäki K. Levels of serum lipids, apolipoprotein A-1 and B and pseudocholinesterase activity and their discriminative values in patients with coronary by-pass operation. Atherosclerosis. 1986;59:215-221.[Medline] [Order article via Infotrieve]
37. Riepponen P, Marniemi J, Rautaoja T. Immunoturbidimetric determination of apolipoproteins A-1 and B in serum. Scand J Clin Lab Invest. 1987;47:739-744.[Medline] [Order article via Infotrieve]
38. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.[Abstract]
39. Lehtimäki T, Moilanen T, Viikari J, Åkerblom HK, Ehnholm C, Rönnemaa T, Marniemi J, Dahlen G, Nikkari T. Apolipoprotein E phenotype in Finnish youths: a cross-sectional and 6-year follow-up study. J Lipid Res. 1990;31:487-495.[Abstract]
40. Maatela J, Marniemi J, Reunanen A, Järvisalo J, Mäki J, Tikkanen MJ. Health-based reference value of the Mini-Finland Health Survey: 2. Cholesterol in total serum and in different lipoprotein fractions. Scand J Clin Lab Invest. 1994;54:33-42.[Medline] [Order article via Infotrieve]
41. Isles CG, Hole DJ, Gillis CR, Hawthorne VM, Lever AF. Plasma cholesterol, coronary heart disease, and cancer in the Renfrew and Paisley survey. BMJ. 1989;298:920-924.
42. Oliver MF. Serum cholesterol—the knave of hearts and the joker. Lancet. 1981;ii:1090-1095.
43. Kannel WB, Gordon T. Evaluation of cardiovascular risk in the elderly: the Framingham Study. Bull N Y Acad Med. 1978;54:573-579.[Medline] [Order article via Infotrieve]
44. Nicholson J, Gartside PS, Siegel M, Spencer W, Steiner PM, Glueck CJ. Lipid and lipoprotein distribution in octo- and nonagenarians. Metabolism. 1979;28:51-55.[Medline] [Order article via Infotrieve]
45. Tervahauta M, Pekkanen J, Kivinen P, Stengård J, Jauhiainen M, Ehnholm C, Nissinen A. Prevalence of coronary heart disease and associated risk factors among elderly Finnish men in the Seven Countries Study. Atherosclerosis. 1993;104:47-59.[Medline] [Order article via Infotrieve]
46.
Lenzen HJ, Assmann G, Buchwalsky R, Schulte
H. Association of apolipoprotein E polymorphism, low density
lipoprotein cholesterol, and coronary artery
disease. Clin Chem. 1986;32:778-781.
47. Wang K. Studies of human apolipoprotein E genetic isoforms and their phenotypes among the Chinese population. Acta Acad Med Sinicae. 1986;8:198.
48. Eto M, Watanabe K, Ishii K. Reciprocal effects of apolipoprotein E alleles (e2 and e4) on plasma lipid levels in normolipidemic subjects. Clin Genet. 1986;29:477-484.[Medline] [Order article via Infotrieve]
49. Pepe MG, Curtiss LK. Apolipoprotein E is biologically active constituent of the normal immunoregulatory lipoprotein, LDL-In. J Immunol. 1986;136:3716-3723.[Abstract]
50.
Mahley RW. Apolipoprotein E:
cholesterol transport protein with expanding role in cell
biology. Science. 1988;240:622-630.
51. Aromaa A, Heliövaara M, Impivaara O, Knekt P, Maatela J, Joukamaa M, Klaukka T, Lehtinen V, Melkas T, Mälkiä E, Nyman K, Paunio I, Reunanen A, Sievers K, Kalimo E, Kallio V. Health, Functional Limitations and Need for Care in Finland: Basic Results From the Mini-Finland Health Survey. Turku, Finland: Social Insurance Institution; 1989;32:112-123.
52.
Rönnemaa T, Laakso M, Kallio V,
Pyörälä K, Marniemi J, Puukka P. Serum lipids,
lipoproteins, and apolipoproteins and the excessive occurrence of
coronary heart disease in non-insulin-dependent diabetic
patients. Am J Epidemiol. 1989;130:632-645.
This article has been cited by other articles:
 |
|
 |
|
  D. C. Ewbank Differences in the Association Between Apolipoprotein E Genotype and Mortality Across Populations J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2007; 62(8): 899 - 907. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Strandberg, A. Strandberg, K. Rantanen, V. V. Salomaa, K. Pitkala, and T. A. Miettinen Low cholesterol, mortality, and quality of life in old age during a 39-year follow-up J. Am. Coll. Cardiol., September 1, 2004; 44(5): 1002 - 1008. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Ravnskov High cholesterol may protect against infections and atherosclerosis QJM, December 1, 2003; 96(12): 927 - 934. [Full Text] [PDF]
|
|
|
|
 |
|
 H. V. Huikuri, T. H. Makikallio, K. E. J. Airaksinen, T. Seppanen, P. Puukka, I. J. Raiha, and L. B. Sourander Power-Law Relationship of Heart Rate Variability as a Predictor of Mortality in the Elderly Circulation, May 26, 1998; 97(20): 2031 - 2036. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||